Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-24
2006-10-24
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S419000, C514S423000, C514S460000, C514S547000, C424S093730, C604S004010, C604S006080
Reexamination Certificate
active
07125897
ABSTRACT:
There is provided a combination treatment for slowing or arresting the progression and/or effecting the regression of atherosclerotic plaque deposits in a mammalian patient, said combination treatment including the administration to the patient of a cholesterol lowering drug such as a statin, and the administration to the patient of an aliquot of a patient's own blood which has been treated ex vivo with one or more stressors selected from an oxidative environment, thermal stress and UV light.
REFERENCES:
patent: 5426116 (1995-06-01), Bisaccia et al.
patent: 5705518 (1998-01-01), Richter et al.
patent: 5980954 (1999-11-01), Bolton
patent: 6264646 (2001-07-01), Stewart
patent: 6432399 (2002-08-01), Tremblay et al.
patent: 2003/0157114 (2003-08-01), Bolton
patent: 2296723 (1999-03-01), None
patent: 96/34613 (1996-11-01), None
patent: 98/07436 (1998-02-01), None
patent: 99/11260 (1999-03-01), None
patent: 99/13890 (1999-03-01), None
patent: 00/29003 (2000-05-01), None
The Merck Manual of Diagnosis and Therapy, Berkow et al. (eds.), published 1982 by Merck & Co., Inc. (NJ), pp. 386-389 and 550-555.
Alegret, M., et al. “Effect of hypolipidemic drugs on key enzyme activities related to lipid metabolism in normolipidemic rabbits.”E. J. Pharmacol. 347: 283-291 (1998).
Bandoh, T., et al. “Fluvastatin Suppresses Atherosclerotic Progression, Mediated Through Its Inhibitory Effect on Endothelial Dysfunction, Lipid Peroxidation, and Macrophage Deposition.”J. Cardio. Pharmacol.35: 134-144 (2000).
Bocan, T.M.A., et al. “Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglytaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation.”Atherosclerosis. 111: 127-142 (1994).
Dowell, F.J., et al. “Development and Progression of Atherosclerosis in Aorta From Heterozygous and Homozygous WHHL Rabbits.”Arteriosclerosis, Thrombosis, and Vascular Biology. 15(8): 1152-1160 (1995).
Gambhir, D.S. “Statin Therapy for Prevention of Coronary Artery Disease with Average Cholesterol Levels.”Indian Heart J.51: 19-21 (1999).
Farnier, M., et al. “Current and Future Treatment of Hyperlipidemia: The Role of Statins.”Am. J. Cardiol.82(48): 3J-10J (1998).
Kroon, A.A., et al. “The effect of cholesterol reduction on the endothelial function and progression of atherosclerosis in WHHL rabbits.”Atherosclerosis. 103(221-230 (1993).
LaRosa, J.C. “Future Cardiovascular End Point Studies: Where Will the Research Take Us?”Am. J. Cardiol.84: 454-458 (1999).
Pederssen, T.R. “Statin trials and goals of cholesterol-lowering therapy after AMI.”Am. Heart J.138: S177-S182 (1999).
Reynolds, J.E.F. “Martindale, the Extra Pharmacopeia, Thirty-second Edition.” London, Royal Pharmaceutical Society. p. 1268-1279. (1994).
Ross, S.D., et al. “Clinical Outcomes in Statin Treatment Trials.”Arch. Intern. Med.159: 1973-1802 (1999).
Vaughan, C.J., et al. “Neuroprotective Properties of Statins in Cerebral Ischemia and Stroke.”Stroke. 30: 1969-1973 (1999).
Wheeler, D.C. “Are There Potential Non-Lipid-Lowering Uses of Statins?”Drugs. 5(6): 517-522 (1998).
Bernini, F., et al. (2001). “Safety of HMG-CoA Reductase Inhibitors: Focus on Atorvastatin,”Cardiovascular Drugs and Therapy, 15:211-218.
Blum, C. (1994). “Comparison of Properties of Four Inhibitors of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase,”Am. J. Cardio,73:3D-11D.
“Compendium of Pharmaceuticals and Specialities, 35thEdition, 2001: The Candian Reference for Health Professionals,” Candaian Pharmacists Association, 815-818, 834-836, 921-923, 1236-1239, 1776-1778.
Hsu, I., et al. (1995). “Comparative Evaluation of the Safety and Efficacy of HMG-CoA Reductase Inhibitor Monotherapy in the Treatment of Primary Hypercholesterolemia,”Ann. Of Pharmac.,29:743-759.
Malhotra, H., et al. (2001). “Atorvastatin: An Updated Review of its Pharmacological Properties and Use in Dyslipidaemia,”Adis Drug Evaluation Drugs, 61(12):1835-1881.
Newman, C., et al. (2003). “Safety of Atorvastatin Derived from Analysis of 44 Completed Trials in 9,416 Patients,”Am. J. Cardio.,92:670-676.
“Lescol,”Physician's Desk Reference,http://www.pdrhealth.com/drug—info/rxdrugprofiles/drugs/les1221.shtml (Feb. 12, 2004).
“Lipitor,”Physician's Desk Reference,http://www.pdrhealth.com/drug—info/rxdrugprofiles/drugs/lip1230.shtml (Feb. 12, 2004).
“Mevacor,”Physician's Desk Reference,http://www.pdrhealth.com/drug—info/rxdrugprofiles/drugs/mev1260.shtml (Feb. 12, 2004).
“Pravachol,”Physician's Desk Reference,http://www.pdrhealth.com/drug—info/rxdrugprofiles/drugs/pra1344.shtml (Feb. 12, 2004).
“Zocor,”Physician's Desk Reference,http://www.pdrhealth.com/drug—info/rxdrugprofiles/drugs/zoc1500.shtml (Feb. 12, 2004).
Athyros et al. “Safety and Efficacy of Long-term Statin-Fibrate Combinations in Patients with Refractory Familial Combined Hyperlipidemia”Am. J. Cardiol.80:608-613 (1997).
Tikkanen, Matti J. “Statins: within-group comparisons, statin escape and combination therapy”Current Opinion in Lipidology7:385-388 (1996).
Orekhov et al. “Antiatherosclerotic and antiatherogeni effects of a calcium antagonist plus statin combination: amlodipine and lovastatin”Int. J. Cardiol.(Suppl. 2):S67-S77 (1997).
Kostner, K.M. “Aggressive Therapie and Kombinationstherapie bie schweren Hyperlipidämien” WMW- May 6, 1999 Themenheft: “HMG-CoA-Reduktase-Hemmer” 1-3.
Feher et al. “Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease”Br. Heart J.74:14-17 (1995).
Orekhov et al. “Anti-Atherogenic Effect of Calcium Antagonist Plus Statin Combination,”Cardiovascular Drugs and Therapy, Kluwer academic Publishers, Boston, U.S. vol. 11, No. 2:350 (1997).
Foley & Lardner LLP
Henley III Raymond J.
Vasogen Ireland Limited
LandOfFree
Combined therapies for atherosclerosis treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combined therapies for atherosclerosis treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combined therapies for atherosclerosis treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3711750